Home The Word Brain My Amedeo FAQ Privacy About   


Amedeo C49

English + 你好 (nǐ hǎo) = limitless possibilities.
Start learning Mandarin Chinese today—for free, forever.

Amedeo C49 is completely free, for life. Next week: +49.


  Lung Cancer

  Free Subscription


Articles published in J Thorac Oncol

Retrieve available abstracts of 333 articles:
HTML format



Single Articles


    June 2025
  1. FUKUDA K, Nanjo S, Takeuchi S, Chakrabarti T, et al
    Targeting WEE1 to overcome ARID1A mutation-driven osimertinib resistance in EGFR-mutant lung cancer.
    J Thorac Oncol. 2025 Jun 13:S1556-0864(25)00766.
    PubMed     Abstract available


  2. PETERS S, Regan MM, Paz-Ares LG, Reck M, et al
    Treatment-Free Survival Over 6 Years of Follow-up in Patients With Metastatic Non-small Cell Lung Cancer Treated With First-Line Nivolumab Plus Ipilimumab Versus Chemotherapy in CheckMate 227 Part 1.
    J Thorac Oncol. 2025 Jun 3:S1556-0864(25)00749.
    PubMed     Abstract available


  3. MASCAUX C, Sen T, Sanchez-Cespedes M, Ortiz-Cuaran S, et al
    Advances in lung cancer basic and translational research in 2025 - Overview and perspectives focusing on non-small cell lung cancer.
    J Thorac Oncol. 2025 Jun 3:S1556-0864(25)00754.
    PubMed     Abstract available


  4. TAMMEMAGI MC, Borondy-Kitts A, Field JF, Mohan A, et al
    A Response to the Letter to the Editor: "Quality Performance Indicators for Lung Cancer Screening: Towards the Next Levels?".
    J Thorac Oncol. 2025;20:e69-e71.
    PubMed    


  5. MEERBEECK JV, Hal GV, Snoeckx A
    Quality Performance Indicators for Lung Cancer Screening: Towards the Next Levels?
    J Thorac Oncol. 2025;20:e68-e69.
    PubMed    


  6. REVEL MP
    Overcoming Barriers to Lung Cancer Screening: The Incidental Pulmonary Nodule Strategy.
    J Thorac Oncol. 2025;20:705-707.
    PubMed    


  7. FU F, Chen H
    Bridging the Gap in Surgery for Octogenarians With Early-Stage Lung Cancer.
    J Thorac Oncol. 2025;20:703-704.
    PubMed    


  8. SCHEFFLER M, Wolf J, Michels S
    Can Immunotherapy Be Omitted in KRAS G12C-Mutant Lung Cancer by 2025?
    J Thorac Oncol. 2025;20:692-694.
    PubMed    


  9. SPIRA AI, Paz-Ares L, Han JY, Shih JY, et al
    Preventing Infusion-Related Reactions With Intravenous Amivantamab-Results From SKIPPirr, a Phase 2 Study: A Brief Report.
    J Thorac Oncol. 2025;20:809-816.
    PubMed     Abstract available


  10. MAO S, Liu X, Wang L, Wang Y, et al
    AYVM to AYMM Transition on HER2 Exon 20 Insertion Induces Tyrosine Kinase Inhibitor Resistance in NSCLC.
    J Thorac Oncol. 2025;20:739-749.
    PubMed     Abstract available


    May 2025
  11. CHADDHA U, Agrawal A, Ghori U, Kheir F, et al
    Safety and Sample Adequacy for Comprehensive Biomarker Testing of Bronchoscopic Biopsies: An American Association of Bronchology and Interventional Pulmonology (AABIP) and International Association for the Study of Lung Cancer (IASLC) Clinical Practic
    J Thorac Oncol. 2025 May 24:S1556-0864(25)00722.
    PubMed     Abstract available


  12. HERBST RS, Cho BC, Zhou C, Burotto M, et al
    Lenvatinib Plus Pembrolizumab, Pemetrexed, and a Platinum as First-Line Therapy for Metastatic Nonsquamous Non-Small-Cell Lung Cancer: Phase 3 LEAP-006 Study.
    J Thorac Oncol. 2025 May 24:S1556-0864(25)00724.
    PubMed     Abstract available


  13. KREBS MG, Cho BC, Hiret S, Han JY, et al
    Amivantamab in Participants with Advanced Non-small Cell Lung Cancer (NSCLC) and MET Exon 14 Skipping Mutations: Final Results From the CHRYSALIS Study.
    J Thorac Oncol. 2025 May 16:S1556-0864(25)00720.
    PubMed     Abstract available


  14. RODE MM, Sykes AG, Allen MS, Ingalls LA, et al
    Risk-Based Lung Cancer Screening in Clinical Practice.
    J Thorac Oncol. 2025 May 14:S1556-0864(25)00717.
    PubMed     Abstract available


  15. JONES SB, Chan C, Filippi AR, Harada K, et al
    Emerging Role of Targeted Therapies Combined with Radiotherapy in Inoperable Stage I-III, Non-Small Cell Lung Cancer (NSCLC): A Review from the International Association for the Study of Lung Cancer (IASLC) Advanced Radiation Technology (ART) Subcommi
    J Thorac Oncol. 2025 May 9:S1556-0864(25)00710.
    PubMed     Abstract available


  16. WIESWEG M, Alaffas A, Rasokat A, Saalfeld FC, et al
    Treatment sequences in BRAF-V600-mutated non-small cell lung cancer: First-line targeted therapy versus first-line (chemo-) immunotherapy.
    J Thorac Oncol. 2025 May 7:S1556-0864(25)00706.
    PubMed     Abstract available


  17. SABARI JK, Yu HA, Mahadevia PJ, Liu Y, et al
    Overall Survival in EGFR-mutant Advanced Non-Small Cell Lung Cancer Treated with First-line Osimertinib: A Cohort Study Integrating Clinical and Biomarker Data in the United States.
    J Thorac Oncol. 2025 May 2:S1556-0864(25)00699.
    PubMed     Abstract available


  18. BOSTOCK I, Fox A, Engelhart K, Farjah F, et al
    Response to Letter to the Editor: "Refining Surgical Decision-Making for Elderly With Lung Cancer Patients: Recognized Risks, Unmet Needs".
    J Thorac Oncol. 2025;20:e63-e64.
    PubMed    


  19. WANG F, Bao M, Zhu L
    Refining Surgical Decision-Making for Elderly Patients With Lung Cancer: Recognized Risks, Unmet Needs.
    J Thorac Oncol. 2025;20:e62-e63.
    PubMed    


  20. MREMI A, Ndumbalo J, Chuwa H, Henke O, et al
    Lung Cancer in Tanzania.
    J Thorac Oncol. 2025;20:560-564.
    PubMed    


  21. DE-TORRES JP, Varo N
    The Tree That Let Us See the Forest: The Importance of Comorbidities in Lung Cancer Screening Programs.
    J Thorac Oncol. 2025;20:555-556.
    PubMed    


  22. YANAGISAWA A, Shiroyama T, Miyake K, Takeda Y, et al
    Diabetic Ketoacidosis During Lorlatinib Treatment: Case Report.
    J Thorac Oncol. 2025;20:676-679.
    PubMed     Abstract available


  23. LINDBERG A, Muhl L, Yu H, Hellberg L, et al
    In Situ Detection of Programmed Cell Death Protein 1 and Programmed Death Ligand 1 Interactions as a Functional Predictor for Response to Immune Checkpoint Inhibition in NSCLC.
    J Thorac Oncol. 2025;20:625-640.
    PubMed     Abstract available


    April 2025
  24. GRONBERG BH, Killingberg KT, Flotten O, Bjaanaes MM, et al
    High-dose versus standard dose twice-daily thoracic radiotherapy in limited stage small-cell lung cancer: final survival data, long-term toxicity and relapse patterns in a randomised, open-label, phase II trial.
    J Thorac Oncol. 2025 Apr 19:S1556-0864(25)00696.
    PubMed     Abstract available


  25. GULDBRANDSEN KF, Bloch M, Skougaard K, Ahlborn LB, et al
    Surveillance with [(18)F]FDG PET/CT of stage I-III lung cancer patients after completion of curative treatment (SUPE_R): a randomized controlled trial.
    J Thorac Oncol. 2025 Apr 19:S1556-0864(25)00693.
    PubMed     Abstract available


  26. HAMADA A, Soh J, Hata A, Nakamatsu K, et al
    Neoadjuvant Concurrent Chemo-immuno-radiation Therapy Followed by Surgery and Adjuvant Immunotherapy for Resectable Stage III N2 Non-Small Cell Lung Cancer: Primary Results from SQUAT trial (WJOG 12119L).
    J Thorac Oncol. 2025 Apr 9:S1556-0864(25)00656.
    PubMed     Abstract available


  27. BOERI M, Zanghi A, Pastorino U
    New Horizons in Lung Cancer Screening: Eligibility Criteria, Risk Models, and Emerging Challenges.
    J Thorac Oncol. 2025;20:422-424.
    PubMed    


  28. KIM YW, Lee CT
    Advancing the Implementation of Risk Model-Based Lung Cancer Screening.
    J Thorac Oncol. 2025;20:419-421.
    PubMed    


  29. PARIKH K, Hashmi A, Chauhan PS, Chaudhuri AA, et al
    Plasma-First Testing in Advanced Lung Cancer: Evidence and Implications.
    J Thorac Oncol. 2025;20:411-414.
    PubMed    


  30. XIA Y, Wang K, Zhao J, Arter Z, et al
    Receptor Tyrosine Kinase Fusion-Mediated Resistance to EGFR TKI in EGFR-Mutant NSCLC: A Multi-Center Analysis and Literature Review.
    J Thorac Oncol. 2025;20:465-474.
    PubMed     Abstract available


  31. NAKAGAWA K, Garon EB, Seto T, Nishio M, et al
    RELAY: Final Overall Survival for Erlotinib Plus Ramucirumab or Placebo in Untreated, EGFR-Mutated Metastatic NSCLC.
    J Thorac Oncol. 2025;20:487-499.
    PubMed     Abstract available


  32. BLECHTER B, Hsiung CA, Wang X, Zhang H, et al
    Polygenic Risk Score and Lung Adenocarcinoma Risk Among Never-Smokers by EGFR Mutation Status: A Brief Report.
    J Thorac Oncol. 2025;20:521-530.
    PubMed     Abstract available


  33. LEUNISSEN DJG, Moonen L, von der Thusen JH, den Bakker MA, et al
    Identification of Defined Molecular Subgroups on the Basis of Immunohistochemical Analyses and Potential Therapeutic Vulnerabilities of Pulmonary Carcinoids.
    J Thorac Oncol. 2025;20:451-464.
    PubMed     Abstract available


    March 2025
  34. SEDER CW, Chang SC, Towe CW, Puri V, et al
    Anatomic Lung Resection is Associated with Improved Survival Compared with Wedge Resection for Stage IA (
    J Thorac Oncol. 2025 Mar 23:S1556-0864(25)00641.
    PubMed     Abstract available


  35. HAKOZAKI T, Tanaka K, Shiraishi Y, Sekino Y, et al
    Gut Microbiota in Advanced Non-small-cell Lung Cancer Receiving Chemo-immunotherapy: An Ancillary Biomarker Study from the Phase III trial JCOG2007 (NIPPON).
    J Thorac Oncol. 2025 Mar 7:S1556-0864(25)00106.
    PubMed     Abstract available


  36. CHEN P, Wang H, Tang Z, Shi J, et al
    Selective depletion of CCR8+Treg cells enhances anti-tumor immunity of cytotoxic T cells in lung cancer via dendritic cells.
    J Thorac Oncol. 2025 Mar 6:S1556-0864(25)00109.
    PubMed     Abstract available


  37. BROWN M, Myers R, Lam S
    Enlarging the Reach of Screening and Early Detection of Lung Cancer.
    J Thorac Oncol. 2025;20:249-251.
    PubMed    


  38. CHOU TY, Dacic S, Wistuba I, Beasley MB, et al
    Differentiating Separate Primary Lung Adenocarcinomas From Intrapulmonary Metastases With Emphasis on Pathological and Molecular Considerations: Recommendations From the International Association for the Study of Lung Cancer Pathology Committee.
    J Thorac Oncol. 2025;20:311-330.
    PubMed     Abstract available


  39. LU S, Wu L, Wang Q, Wang Z, et al
    Durvalumab Versus Chemotherapy as First-line Treatment for Metastatic NSCLC With Tumor PD-L1 Expression of 25% or Higher: Results From the Randomized Phase 3 PEARL Study.
    J Thorac Oncol. 2025;20:366-382.
    PubMed     Abstract available


  40. MARINELLI D, Nuccio A, Di Federico A, Ambrosi F, et al
    Improved Event-Free Survival After Complete or Major Pathologic Response in Patients With Resectable NSCLC Treated With Neoadjuvant Chemoimmunotherapy Regardless of Adjuvant Treatment: A Systematic Review and Individual Patient Data Meta-Analysis.
    J Thorac Oncol. 2025;20:285-295.
    PubMed     Abstract available


    February 2025
  41. XIE D, Zhang L, He N, Yang C, et al
    Overdiagnosis of Lung Cancer due to Introduction of Low-Dose Computed Tomography in Average-Risk Populations in China.
    J Thorac Oncol. 2025 Feb 13:S1556-0864(25)00072.
    PubMed     Abstract available


  42. CALLES A, Navarro A, Doger Speville Uribe BG, Alvarez Colome E, et al
    Lurbinectedin plus pembrolizumab in relapsed small cell lung cancer (SCLC): the phase I/II LUPER study.
    J Thorac Oncol. 2025 Feb 10:S1556-0864(25)00064.
    PubMed     Abstract available


  43. FONG KM, Rosenthal A, Giroux DJ, Nishimura KK, et al
    Corrigendum to 'The International Association for the Study of Lung Cancer Staging Project for Lung Cancer: Proposals for the Revision of the M Descriptors in the Forthcoming Ninth Edition of the TNM Classification for Lung Cancer' [Journal of Thoraci
    J Thorac Oncol. 2025 Feb 9:S1556-0864(25)00050.
    PubMed    


  44. HAN B, Liu J, Wu L, Zhao Y, et al
    Safety, Pharmacokinetics, and Efficacy of TY-9591 (Deuterated Osimertinib Derivative) in Advanced EGFR-mutated Non-Small Cell Lung Cancer: A Phase 1 Dose-Escalation and Dose-Expansion Study.
    J Thorac Oncol. 2025 Feb 8:S1556-0864(25)00062.
    PubMed     Abstract available


  45. LI YS, Yu Q, Bu Q, Lin L, et al
    First-Line Camrelizumab versus Placebo Plus Chemotherapy with or without Radiotherapy for Brain Metastases in Non-Small-Cell Lung Cancer: The CTONG 2003 Randomized Placebo-Controlled Trial.
    J Thorac Oncol. 2025 Feb 8:S1556-0864(25)00063.
    PubMed     Abstract available


  46. ABBAR B, Labreche K, Cadranel J, Veyri M, et al
    HIV Impairs Immune Responses to Tumor Neoepitopes Without Altering Mutational Profiles in Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2025 Feb 7:S1556-0864(25)00060.
    PubMed     Abstract available


  47. SILVESTRI GA, Young R, Tanner NT, Mazzone P, et al
    A Response to the Letter to the Editor: "Failure to Include Nonsmokers in Computed Tomography Screening for Lung Cancer is Unjust".
    J Thorac Oncol. 2025;20:e39-e40.
    PubMed    


  48. SILVESTRI GA, Young R, Tanner NT, Mazzone P, et al
    A Response to the Letter to the Editor: "Lung Cancer Screening in Low-Risk Populations: Ethical Considerations, Technological Advancements, and Socioeconomic Challenges".
    J Thorac Oncol. 2025;20:e36-e37.
    PubMed    


  49. LI J, Zhang Y, Fu T, Tong Y, et al
    Lung Cancer Screening in Low-Risk Populations: Ethical Considerations, Technological Advancements, and Socioeconomic Challenges.
    J Thorac Oncol. 2025;20:e35-e36.
    PubMed    


  50. SILVESTRI GA, Young R, Tanner NT, Mazzone P, et al
    A Response to the Letter to the Editor: "Secondhand Smoke in Low-Risk Groups: A Hidden Danger in Lung Cancer Screening".
    J Thorac Oncol. 2025;20:e34.
    PubMed    


  51. CUI Y
    Secondhand Smoke in Low-Risk Groups: A Hidden Danger in Lung Cancer Screening.
    J Thorac Oncol. 2025;20:e33-e34.
    PubMed    


  52. RIZZO MM, Barros M, Chimondeguy D, Dalurzo ML, et al
    Lung Cancer in Argentina.
    J Thorac Oncol. 2025;20:144-149.
    PubMed    


  53. BAK M, Park H, Lee SH, Lee N, et al
    The Risk and Reversibility of Osimertinib-Related Cardiotoxicity in a Real-World Population.
    J Thorac Oncol. 2025;20:167-176.
    PubMed     Abstract available


  54. NAKAGAWA K, Watanabe SI, Wakabayashi M, Yotsukura M, et al
    Risk Factors for Locoregional Relapse After Segmentectomy: Supplementary Analysis of the JCOG0802/WJOG4607L Trial.
    J Thorac Oncol. 2025;20:157-166.
    PubMed     Abstract available


  55. LEE J, Jeon JH, Chung JH, Son JW, et al
    Prognostic Impact of Non-Predominant Lepidic Components in Pathologic Stage I Invasive Nonmucinous Adenocarcinoma.
    J Thorac Oncol. 2025;20:194-202.
    PubMed     Abstract available


    January 2025
  56. LIAO W, Ray MA, Patel A, Roma J, et al
    Barriers to Lung Cancer Screening in a Multi-Disciplinary Thoracic Oncology Program Cohort: Effects of an Incidental Pulmonary Nodule Program.
    J Thorac Oncol. 2025 Jan 30:S1556-0864(25)00057.
    PubMed     Abstract available


  57. BOSTOCK IC, Fox AH, Ward RC, Engelhardt KE, et al
    Outcomes After Surgical Management of Early-Stage Lung Cancer in Octogenarians: An in-depth Analysis of a Nationally Representative Cohort.
    J Thorac Oncol. 2025 Jan 28:S1556-0864(25)00053.
    PubMed     Abstract available


  58. TAMMEMAGI MC, Borondy-Kitts A, Field JK, Henschke CI, et al
    Lung cancer screening program quality indicators - review & recommendations - An International Association for the Study of Lung Cancer Delphi process study.
    J Thorac Oncol. 2025 Jan 24:S1556-0864(25)00052.
    PubMed     Abstract available


  59. GANDHI MM, Elkrief A, Moore CG, Ricciuti B, et al
    Gene copy deletion of STK11, KEAP1, and SMARCA4: clinicopathologic features and association with outcomes to immunotherapy +/- chemotherapy in nonsquamous non-small cell lung cancer.
    J Thorac Oncol. 2025 Jan 24:S1556-0864(25)00049.
    PubMed     Abstract available


  60. TSAO MS, Rosenthal A, Nicholson AG, Detterbeck F, et al
    The International Association for the Study of Lung Cancer Staging Project: The Database and Proposal for the Revision of the Staging of Pulmonary Neuroendocrine Carcinoma in the Forthcoming Ninth Edition of the TNM Classification for Lung Cancer.
    J Thorac Oncol. 2025 Jan 24:S1556-0864(25)00046.
    PubMed     Abstract available


  61. AKAMATSU H, Sakata S, Azuma K, Yoshioka H, et al
    A single-arm, phase II study of sotorasib plus carboplatin/pemetrexed in advanced non-squamous non-small cell lung cancer patients with KRAS G12C mutation (WJOG14821L, SCARLET).
    J Thorac Oncol. 2025 Jan 17:S1556-0864(25)00007.
    PubMed     Abstract available


  62. GENDARME S, Irajizad E, Long JP, Fahrmann JF, et al
    Impact of comorbidities on the mortality benefits of lung cancer screening: a post-hoc analysis of PLCO and NLST trials.
    J Thorac Oncol. 2025 Jan 9:S1556-0864(25)00004.
    PubMed     Abstract available


  63. BESSE B, Goto K, Wang Y, Lee SH, et al
    Amivantamab Plus Lazertinib in Patients With EGFR-mutant Non-small Cell Lung Cancer (NSCLC) After Progression on Osimertinib and Platinum-based Chemotherapy: Results From CHRYSALIS-2 Cohort A.
    J Thorac Oncol. 2025 Jan 2:S1556-0864(24)02550.
    PubMed     Abstract available


  64. FUKUI T, Mamesaya N, Takahashi T, Kishi K, et al
    A Prospective Phase II Trial of First-line Osimertinib for Patients with EGFR Mutation-positive Non-small Cell Lung Cancer and Poor Performance Status (OPEN/TORG2040).
    J Thorac Oncol. 2025 Jan 2:S1556-0864(24)02548.
    PubMed     Abstract available


  65. DOWLATI A, Chiang AC, Cervantes A, Babu S, et al
    Phase 2 Open-Label Study of Sacituzumab Govitecan as Second-Line Therapy in Patients With Extensive-Stage Small Cell Lung Cancer: Results From TROPiCS-03.
    J Thorac Oncol. 2025 Jan 2:S1556-0864(24)02549.
    PubMed     Abstract available


  66. HUBER RM, Lam S, Cavic M, Balata H, et al
    Response to the Letters to the Editor by Jing Peng and Colleagues and by Lauren C Leiman Regarding the Manuscript "Terminology Issues in Screening and Early Detection of Lung Cancer-International Association for the Study of Lung Cancer Early Detectio
    J Thorac Oncol. 2025;20:e6-e8.
    PubMed    


  67. PENG J, Zhao L, Shan D
    Enhancing Clinical Precision and Patient Communication in Lung Cancer Screening.
    J Thorac Oncol. 2025;20:e3-e4.
    PubMed    


  68. GADGEEL SM, Jensen E, Shamoun M, Rajagopalan K, et al
    Response to: Enhancing Clinical Practice: Critical Insights for Medical Workers in Applying Pembrolizumab for Metastatic NSCLC and Pembrolizumab, Chemotherapy and Metastatic Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2025;20:e11-e12.
    PubMed    


  69. BORGHAEI H, Mok T
    Leptomeningeal Disease in Lung Cancer: An Unmet Need That Needs to Be Met.
    J Thorac Oncol. 2025;20:17-19.
    PubMed    


  70. LI HJ, Qiu ZB, Wang MM, Zhang C, et al
    Radiomics-Based Support Vector Machine Distinguishes Molecular Events Driving the Progression of Lung Adenocarcinoma.
    J Thorac Oncol. 2025;20:52-64.
    PubMed     Abstract available


  71. PETERS S, Cho BC, Luft AV, Alatorre-Alexander J, et al
    Durvalumab With or Without Tremelimumab in Combination With Chemotherapy in First-Line Metastatic NSCLC: Five-Year Overall Survival Outcomes From the Phase 3 POSEIDON Trial.
    J Thorac Oncol. 2025;20:76-93.
    PubMed     Abstract available


    December 2024
  72. WARKENTIN MT, Tammemagi MC, Vakil E, Bedard ELR, et al
    Brief Report: Evaluating Early-Stage Lung Cancer Survival Patterns in Patients at the Upper Age Limit for Lung Cancer Screening.
    J Thorac Oncol. 2024 Dec 30:S1556-0864(24)02546.
    PubMed     Abstract available


  73. LEE JB, Choi SJ, Shim HS, Park BJ, et al
    Neoadjuvant and adjuvant osimertinib in stage IA-IIIA, EGFR-mutant non-small cell lung cancer (NORA).
    J Thorac Oncol. 2024 Dec 26:S1556-0864(24)02544.
    PubMed     Abstract available


  74. GABE R, Crosbie PAJ, Vulkan D, Bailey H, et al
    Prospective evaluation of lung cancer screening eligibility criteria and lung cancer detection in the Yorkshire Lung Screening Trial.
    J Thorac Oncol. 2024 Dec 19:S1556-0864(24)02535.
    PubMed     Abstract available


  75. PASSIGLIA F, Listi A, Bironzo P, Merlini A, et al
    Actionable non-small cell lung cancer mutation identification by comprehensive genomic profiling for clinical trial enrollment: the European Program for the ROutine testing of Patients with Advanced lung cancer (EPROPA).
    J Thorac Oncol. 2024 Dec 16:S1556-0864(24)02529.
    PubMed     Abstract available


  76. SWALDUZ A, Schiffler C, Curcio H, Ambasager B, et al
    LIBELULE: a randomized phase III study to evaluate the clinical relevance of early liquid biopsy in patients with suspicious metastatic lung cancer.
    J Thorac Oncol. 2024 Dec 16:S1556-0864(24)02530.
    PubMed     Abstract available


  77. TAVERNARI D, Borgeaud M, Liu X, Kaushal P, et al
    Decoding the Clinical and Molecular Signatures of EGFR Common, Compound, and Uncommon Mutations in Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2024 Dec 16:S1556-0864(24)02531.
    PubMed     Abstract available


  78. HOFFMANN H, Nicholson AG, Detterbeck FC, Tsao MS, et al
    The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Application and Interpretation of the Residual Tumor (R) Classification for Lung Cancer. Results from an International Survey among Pathologists and Thoracic Surge
    J Thorac Oncol. 2024 Dec 13:S1556-0864(24)02526.
    PubMed     Abstract available


  79. KIM SY, Silvestri GA, Kim YW, Kim RY, et al
    Screening for Lung Cancer, Overdiagnosis, and Healthcare Utilization: A Nationwide Population-Based Study.
    J Thorac Oncol. 2024 Dec 9:S1556-0864(24)02503.
    PubMed     Abstract available


  80. PHILLIPS WJ, Watson AS, Camidge DR
    The use of investigator-assigned subjective or judgmental efficacy and toxicity reporting in early phase clinical trials of lung cancer treatments.
    J Thorac Oncol. 2024 Dec 4:S1556-0864(24)02498.
    PubMed     Abstract available


  81. XU X, Xie J, Luo Z
    Strengthening the Evidence: Expanding Research on Passive Smoking and Lung Cancer.
    J Thorac Oncol. 2024;19:e94-e95.
    PubMed    


  82. LI Z, Liu J, Liu H, Wu C, et al
    Comment on "A Real-World Assessment of Stage I Lung Cancer Through Electronic Nose Technology".
    J Thorac Oncol. 2024;19:e89-e90.
    PubMed    


  83. ZHOU RX, Ye DW
    Reply to the Letter to the Editor: The Relationship Between Air Pollution and Lung Cancer: Differences in Sensitivity Across Regions and Populations.
    J Thorac Oncol. 2024;19:e82-e84.
    PubMed    


  84. WANG L, Wang Z, Wang G
    The Relationship Between Air Pollution and Lung Cancer: Differences in Sensitivity Across Regions and Populations.
    J Thorac Oncol. 2024;19:e81-e82.
    PubMed    


  85. JENSEN SO, Moore DA, Surani AA, Crosbie PAJ, et al
    Second Primary Lung Cancer-Potential Areas of Ambiguity.
    J Thorac Oncol. 2024;19:e101-e102.
    PubMed    


  86. NIU Y, Xie J, Li Z
    Second Primary Lung Cancer-Potential Areas of Ambiguity.
    J Thorac Oncol. 2024;19:e100-e101.
    PubMed    


  87. GUISSEVE A, Mualinque A, Cossa M, Jerez AD, et al
    Lung Cancer in Mozambique.
    J Thorac Oncol. 2024;19:1599-1605.
    PubMed    


  88. TONG BC, Stinchcombe TE
    Lung Cancer Screening and Early Detection Terminology: Time to Sing From the Same Song Sheet.
    J Thorac Oncol. 2024;19:1589-1590.
    PubMed    


  89. KOZONO D, Hua X, Wu MC, Tolba KA, et al
    Lung-MAP Next-Generation Sequencing Analysis of Advanced Squamous Cell Lung Cancers (SWOG S1400).
    J Thorac Oncol. 2024;19:1618-1629.
    PubMed     Abstract available


    November 2024
  90. HEERSCHE N, Lanser DAC, Muntinghe-Wagenaar MB, Mohmaed Ali MI, et al
    Sex and common germline variants impact the toxicity profile and pharmacokinetics of alectinib: a nation-wide cohort study in patients with ALK-positive non-small cell lung cancer.
    J Thorac Oncol. 2024 Nov 29:S1556-0864(24)02488.
    PubMed     Abstract available


  91. KAZI A, Kantilal Vasiyani HK, Ghosh D, Bandyopadhyay D, et al
    FGTI-2734 Inhibits ERK Reactivation to Overcome Sotorasib Resistance in KRAS G12C Lung Cancer.
    J Thorac Oncol. 2024 Nov 25:S1556-0864(24)02485.
    PubMed     Abstract available


  92. IGNATIUS OU SH, Solomon BJ, Besse B, Bearz A, et al
    Brief Report: Final overall survival and long-term safety of lorlatinib in patients with ALK-positive non-small cell lung cancer from the pivotal phase 2 study.
    J Thorac Oncol. 2024 Nov 22:S1556-0864(24)02484.
    PubMed     Abstract available


  93. DAMARAJU V, Krushna Karri JK, Gandrakota G, Marimuthu Y, et al
    Low dose computed tomography for lung cancer screening in Tuberculosis endemic countries: A Systematic Review and Meta-analysis.
    J Thorac Oncol. 2024 Nov 22:S1556-0864(24)02483.
    PubMed     Abstract available


  94. LEVY A, Rusthoven CG, Brown PD, Le Pechoux C, et al
    PCI for Patients with Small Cell Lung Cancer: A New Perspective in the Immunotherapy Era.
    J Thorac Oncol. 2024 Nov 15:S1556-0864(24)02446.
    PubMed     Abstract available


  95. ZHAO S, Zhou H, Yang N, Wang Z, et al
    Safety, efficacy and biomarker analysis of deulorlatinib (TGRX-326) in ALK-positive non-small-cell lung cancer: a multicentre, open-label, phase 1/1b trial.
    J Thorac Oncol. 2024 Nov 15:S1556-0864(24)02445.
    PubMed     Abstract available


  96. TUMINELLO S, Flores R, Untalan M, Ivic-Pavlicic T, et al
    Predicted effect of incidental pulmonary nodule findings on Non-Small Cell Lung Cancer mortality.
    J Thorac Oncol. 2024 Nov 12:S1556-0864(24)02444.
    PubMed     Abstract available


  97. ECHEPARE M, Picabea B, Arricibita A, Teijeira A, et al
    DSTYK Inhibition Sensitizes Non-Small Cell Lung Cancer To Taxane-Based Chemotherapy.
    J Thorac Oncol. 2024 Nov 11:S1556-0864(24)02438.
    PubMed     Abstract available


  98. GRAY JE, Schenker M, Nahit Sendur MA, Leonova V, et al
    The Phase 3 KEYLYNK-006 Study of Pembrolizumab plus Olaparib versus Pembrolizumab plus Pemetrexed as Maintenance Therapy for Metastatic Nonsquamous Non-Small-Cell Lung Cancer.
    J Thorac Oncol. 2024 Nov 7:S1556-0864(24)02435.
    PubMed     Abstract available


  99. KARIM NA, Miao J, Reckamp KL, Gay CM, et al
    Phase II randomized study of maintenance atezolizumab (A) versus atezolizumab + talazoparib (AT) in patients with SLFN11 positive extensive stage small cell lung cancer. S1929.
    J Thorac Oncol. 2024 Nov 4:S1556-0864(24)02431.
    PubMed     Abstract available


  100. OLTEANU GE, Vigdorovits A, Barna RA, Mazilu L, et al
    Lung Cancer in Romania.
    J Thorac Oncol. 2024;19:1492-1503.
    PubMed    


  101. D'AMOURS MF, Hughesman CB, Yip ST, Ho C, et al
    The Game is Afoot - Seeking Early-Stage Lung Cancer Circulating Tumor DNA.
    J Thorac Oncol. 2024;19:1479-1481.
    PubMed    


  102. ADJEI AA
    How Can We Conquer Lung Cancer?
    J Thorac Oncol. 2024;19:1477-1478.
    PubMed    


  103. KINDLER HL, Rosenthal A, Giroux DJ, Nowak AK, et al
    The International Association for the Study of Lung Cancer Mesothelioma Staging Project: Proposals for the M Descriptors in the Forthcoming Ninth Edition of the TNM Classification for Pleural Mesothelioma.
    J Thorac Oncol. 2024;19:1564-1577.
    PubMed     Abstract available


  104. PARIKH K, Dimou A, Leventakos K, Mansfield AS, et al
    Impact of EML4-ALK Variants and Co-Occurring TP53 Mutations on Duration of First-Line ALK Tyrosine Kinase Inhibitor Treatment and Overall Survival in ALK Fusion-Positive NSCLC: Real-World Outcomes From the GuardantINFORM database.
    J Thorac Oncol. 2024;19:1539-1549.
    PubMed     Abstract available


  105. HONG TH, Hwang S, Dasgupta A, Abbosh C, et al
    Clinical Utility of Tumor-Naive Presurgical Circulating Tumor DNA Detection in Early-Stage NSCLC.
    J Thorac Oncol. 2024;19:1512-1524.
    PubMed     Abstract available


    October 2024
  106. HOCHMAIR M, Schenker M, Dols MC, Kim TM, et al
    Pembrolizumab With or Without Maintenance Olaparib for Metastatic Squamous Non-Small-Cell Lung Cancer That Responded to First-Line Pembrolizumab Plus Chemotherapy.
    J Thorac Oncol. 2024 Oct 28:S1556-0864(24)02420.
    PubMed     Abstract available


  107. CHEN Z, Wu L, Wang Q, Yu Y, et al
    Brief report: Ivonescimab combined with etoposide plus carboplatin as first-line treatment for extensive-stage small-cell lung cancer: results of a phase Ib clinical trial.
    J Thorac Oncol. 2024 Oct 26:S1556-0864(24)02421.
    PubMed     Abstract available


  108. UMEMURA S, Udagawa H, Ikeda T, Murakami H, et al
    Clinical significance of a prospective large genomic screening for small-cell lung cancer: the genetic classification and a biomarker driven phase II trial of gedatolisib.
    J Thorac Oncol. 2024 Oct 10:S1556-0864(24)02378.
    PubMed     Abstract available


  109. PETERS S, Paz-Ares LG, Reck M, Carbone DP, et al
    Long-Term Survival Outcomes With First-Line Nivolumab Plus Ipilimumab-Based Treatment in Patients With Metastatic Non-Small Cell Lung Cancer and Tumor PD-L1 <1%: a Pooled Analysis.
    J Thorac Oncol. 2024 Oct 4:S1556-0864(24)02355.
    PubMed     Abstract available


  110. LEVY A, Adebahr S, Hurkmans C, Fortpied C, et al
    A Response to the Letter to the Editor: "Comment on Stereotactic Body Radiotherapy for Centrally Located Inoperable Early Stage NSCLC: EORTC 22113-08113 LungTech Phase II Trial Results".
    J Thorac Oncol. 2024;19:e57-e59.
    PubMed    


  111. XU Z, Jiang J, Guo H, Zhao D, et al
    Comment on "Stereotactic Body Radiotherapy for Centrally Located Inoperable Early-Stage NSCLC: EORTC 22113-08113 LungTech Phase II Trial Results".
    J Thorac Oncol. 2024;19:e56-e57.
    PubMed    


  112. RAMI-PORTA R, Call S, Sanz-Santos J
    Reply to "Impact of the Ninth IASLC TNM Classification on Endobronchial Ultrasound for Lung Cancer Staging" by Faria et al.
    J Thorac Oncol. 2024;19:e55-e56.
    PubMed    


  113. FARIA N, Costa MI, Lacerda C, Sucena M, et al
    Impact of the Ninth International Association for the Study of Lung Cancer TNM Classification on Endobronchial Ultrasound for Lung Cancer Staging.
    J Thorac Oncol. 2024;19:e53-e55.
    PubMed    


  114. KOHNO T, Mochizuki A
    Response to Letter to the Editor.
    J Thorac Oncol. 2024;19:e52-e53.
    PubMed    


  115. GU X, Han Z, Shi W
    Comment on "Passive Smoking-Induced Mutagenesis as a Promoter of Lung Carcinogenesis".
    J Thorac Oncol. 2024;19:e51-e52.
    PubMed    


  116. ZHUANG WT, Hu LY, Fang WF
    Response to Commentary on "EGFR Oncogenic Mutations in NSCLC Impair Macrophage Phagocytosis and Mediate Innate Immune Evasion Through Up-Regulation of CD47".
    J Thorac Oncol. 2024;19:e50-e51.
    PubMed    


  117. PAN Y
    Comment on "EGFR Oncogenic Mutations in NSCLC Impair Macrophage Phagocytosis and Mediate Innate Immune Evasion Through Up-Regulation of CD47".
    J Thorac Oncol. 2024;19:e49-e50.
    PubMed    


  118. SHI Y
    A Response to the Letter to the Editor: Response to Ficonalkib's Promise and the Path Forward: A Comment on Advanced ALK-Positive NSCLC Treatment.
    J Thorac Oncol. 2024;19:e48.
    PubMed    


  119. GE MW, Chen HL
    Ficonalkib's Promise and the Path Forward: A Comment on Advanced ALK-Positive NSCLC Treatment.
    J Thorac Oncol. 2024;19:e47-e48.
    PubMed    


  120. CABALLE-PEREZ E, Cabrera-Miranda L, Arrieta O
    Exploring EGFR Mutations in Resected Stage I-III NSCLC in Low- and Middle-Income Countries: Bridging the Gap in Global Cancer Care.
    J Thorac Oncol. 2024;19:1367-1369.
    PubMed    


  121. PUJOL JL, Erich Eberhardt WE
    Familial Lung Cancers Caused by EGFR Germline Mutations: The Frequency Is Probably Underestimated but Specific Genotypic Features and Some Particular Disease Characteristics Should Help Their Screening.
    J Thorac Oncol. 2024;19:1364-1366.
    PubMed    


  122. SOO RA, Reungwetwattana T, Perroud HA, Batra U, et al
    Prevalence of EGFR Mutations in Patients With Resected Stages I to III NSCLC: Results From the EARLY-EGFR Study.
    J Thorac Oncol. 2024;19:1449-1459.
    PubMed     Abstract available


  123. PAN K, Owens J, Elamin Y, Lu C, et al
    Mutational Characteristics and Clinical Outcomes for Lung Adenocarcinoma With EGFR Germline Mutations.
    J Thorac Oncol. 2024;19:1438-1448.
    PubMed     Abstract available


  124. BUROTTO M, Zvirbule Z, Alvarez R, Chewaskulyong B, et al
    Brief Report: Updated Data From IMscin001 Part 2, a Randomized Phase III Study of Subcutaneous Versus Intravenous Atezolizumab in Patients With Locally Advanced or Metastatic NSCLC.
    J Thorac Oncol. 2024;19:1460-1466.
    PubMed     Abstract available


    September 2024
  125. SAID BI, Geng Y, Badiyan SN, Bang A, et al
    Accelerated hypofractionated radiotherapy for locally-advanced non-small cell lung cancer: A systematic review from the International Association for the Study of Lung Cancer (IASLC) Advanced Radiation Technology (ART) Subcommittee.
    J Thorac Oncol. 2024 Sep 28:S1556-0864(24)02353.
    PubMed     Abstract available


  126. PARK HS, Rimner A, Amini A, Chang JY, et al
    Executive Summary of the American Radium Society(R) (ARS) Appropriate Use Criteria (AUC) for Non-Small Cell Lung Cancer in a Central/Ultra-Central Location: Systematic Review and Guidelines.
    J Thorac Oncol. 2024 Sep 11:S1556-0864(24)02268.
    PubMed     Abstract available


  127. NASSAR AH, Jayakrishnan R, Feng J, Shepherd F, et al
    Consolidation ALK Tyrosine Kinase Inhibitors versus Durvalumab or Observation After Chemoradiation in Unresectable Stage III ALK+ Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2024 Sep 9:S1556-0864(24)02265.
    PubMed     Abstract available


  128. CHEN H, Yang S, Wang L, Wu Y, et al
    High-dose Furmonertinib in patients with EGFR-mutated non-small cell lung cancer and leptomeningeal metastases: A prospective real-world study.
    J Thorac Oncol. 2024 Sep 9:S1556-0864(24)02269.
    PubMed     Abstract available


  129. HORNE A, Harada K, Brown KD, Lee Min Chua K, et al
    Erratum to "Treatment response biomarkers: working towards personalised radiotherapy for lung cancer. [Journal of Thoracic Oncology Vol. 19 No. 8: 1164-1185]".
    J Thorac Oncol. 2024 Sep 5:S1556-0864(24)00775.
    PubMed    


  130. ERNST SM, von der Thusen JH, Dubbink HJ, Dingemans AC, et al
    A Response to the Letter to the Editor: Comment on "Clinical Utility of Circulating Tumor DNA in Patients With Advanced KRAS(G12C)-Mutated NSCLC Treated With Sotorasib".
    J Thorac Oncol. 2024;19:e44-e45.
    PubMed    


  131. JIANG Y, Zhang L
    Comment on "Clinical Utility of Circulating Tumor DNA in Patients With Advanced KRAS(G12C)-Mutated NSCLC Treated With Sotorasib".
    J Thorac Oncol. 2024;19:e43.
    PubMed    


  132. LEVY A, Adebahr S, Hurkmans C, Fortpied C, et al
    A Response to the Letter to the Editor: The Role of Personalization and Standardization in Stereotactic Body Radiation Therapy.
    J Thorac Oncol. 2024;19:e41-e43.
    PubMed    


  133. ROMA L, Bubendorf L
    Suggestions for Improving the Comprehensive Characterization of Lung Pleomorphic Carcinoma.
    J Thorac Oncol. 2024;19:e38-e39.
    PubMed    


  134. ZHOU L, Li M, Li W
    Suggestions for Improving the Comprehensive Characterization of Lung Pleomorphic Carcinoma.
    J Thorac Oncol. 2024;19:e37-e38.
    PubMed    


  135. TUMINELLO S, Gulati S, Ivic-Pavlicic T, Flores R, et al
    Response to: "The Value of Incidental Imaging for Early Stage Lung Cancer in High-Risk Nonscreening Cohort: Some Additional Considerations?".
    J Thorac Oncol. 2024;19:e36.
    PubMed    


  136. NIU Y, Xie J, Li Z
    The Value of Incidental Imaging for Early-Stage Lung Cancer in a High-Risk Non-Screening Cohort: Some Additional Considerations?
    J Thorac Oncol. 2024;19:e34-e35.
    PubMed    


  137. HIGASHIYAMA RI, Yoshida T
    A Response to the Letter to the Editor: Safety Implications of Switching Pembrolizumab Dosage From 200 mg Every 3 Weeks to 400 mg Every 6 Weeks in Patients With Advanced NSCLC.
    J Thorac Oncol. 2024;19:e33-e34.
    PubMed    


  138. HAN Z, Liu L, Jiang Y
    Suggestions for the predictive factors related to irAES and research methods during dose switching of pembrolizumab treatment in patients with advanced NSCLC.
    J Thorac Oncol. 2024;19:e31-e32.
    PubMed    


  139. ANDERSEN H, Aro M, Kaarteenaho R, Koivunen J, et al
    Lung Cancer in Finland.
    J Thorac Oncol. 2024;19:1265-1271.
    PubMed    


  140. YANG CY, Lee MR, Yang PC
    Beyond Low-Dose Computed Tomography: Emerging Diagnostic Tools for Early Lung Cancer Detection.
    J Thorac Oncol. 2024;19:1261-1264.
    PubMed    


  141. ROSSI S, Costa R, di Federico A, Lo Bianco F, et al
    Histopathological Evidence for a Non-Inflammatory Mechanism in Osimertinib-Induced Myopathy: A Case Report.
    J Thorac Oncol. 2024;19:1352-1355.
    PubMed     Abstract available


  142. LEVY A, Adebahr S, Hurkmans C, Ahmed M, et al
    Stereotactic Body Radiotherapy for Centrally Located Inoperable Early-Stage NSCLC: EORTC 22113-08113 LungTech Phase II Trial Results.
    J Thorac Oncol. 2024;19:1297-1309.
    PubMed     Abstract available


  143. ROMA L, Ercan C, Conticelli F, Akyurek N, et al
    Tracing Tumor Heterogeneity of Pleomorphic Carcinoma of the Lung.
    J Thorac Oncol. 2024;19:1284-1296.
    PubMed     Abstract available


  144. GILL RR, Nowak AK, Giroux DJ, Eisele M, et al
    The International Association for the Study of Lung Cancer Mesothelioma Staging Project: Proposals for Revisions of the "T" Descriptors in the Forthcoming Ninth Edition of the TNM Classification for Pleural Mesothelioma.
    J Thorac Oncol. 2024;19:1310-1325.
    PubMed     Abstract available


    August 2024
  145. ZHOU Q, Meng X, Sun L, Huang D, et al
    Efficacy and safety of KRAS G12C inhibitor IBI351 monotherapy in patients with advanced non-small cell lung cancer: results from a phase 2 pivotal study.
    J Thorac Oncol. 2024 Aug 8:S1556-0864(24)00762.
    PubMed     Abstract available


  146. HUBER RM, Cavic M, Balata H, Kitts AB, et al
    From the IASLC Early Detection and Screening Committee Terminology Issues in Screening and Early Detection of Lung Cancer - IASLC Early Detection and Screening Committee Expert Group Recommendations.
    J Thorac Oncol. 2024 Aug 2:S1556-0864(24)00747.
    PubMed     Abstract available


  147. ERNST SM, von der Thusen JH, Dubbink HJ, Dingemans AC, et al
    Letter Regarding "Clinical Utility of Circulating Tumor DNA in Patients With Advanced KRASG12C-Mutated NSCLC Treated With Sotorasib".
    J Thorac Oncol. 2024;19:e29-e30.
    PubMed    


  148. KOSAKA N, Kataoka Y
    Letter Regarding "Clinical Utility of Circulating Tumor DNA in Patients With Advanced KRASG12C-Mutated NSCLC Treated With Sotorasib".
    J Thorac Oncol. 2024;19:e28.
    PubMed    


  149. CAMERON RB, Hines JB, Torri V, Garassino MC, et al
    A Response Letter by Cameron et al.
    J Thorac Oncol. 2024;19:e26-e28.
    PubMed    


  150. HUANG J, Osarogiagbon RU
    Author's Reply.
    J Thorac Oncol. 2024;19:e24.
    PubMed    


  151. PONVILAWAN B, Subramanian J, Bansal D
    The Number of Chemoimmunotherapy Cycles and Clinical Outcomes in Resectable NSCLC.
    J Thorac Oncol. 2024;19:e24-e26.
    PubMed    


  152. TRISOLINI R
    The Devil Is in the Details: A Hidden Obstacle to Implementing the Proposed Revision of the N Descriptors in the Ninth Edition of the TNM Classification for Lung Cancer.
    J Thorac Oncol. 2024;19:e23.
    PubMed    


  153. KUBO N
    Response to Letter to the Editor.
    J Thorac Oncol. 2024;19:e22.
    PubMed    


  154. SHI L, Bao Z
    Accurate Prognostic Factor for Carbon-Ion Radiotherapy in Operable Stage I NSCLC.
    J Thorac Oncol. 2024;19:e21-e22.
    PubMed    


  155. SILVESTRI GA, Young RP, Tanner NT, Mazzone P, et al
    Screening Low-Risk Individuals for Lung Cancer: The Need May Be Present, but the Evidence of Benefit Is Not.
    J Thorac Oncol. 2024;19:1155-1163.
    PubMed     Abstract available


  156. MAKAREM M, Janne PA
    "Tumor-Free Survival" Outweighs the Side Effects of Combined Anti-EGF Therapy and Chemotherapy in Patients With NSCLC.
    J Thorac Oncol. 2024;19:1151-1154.
    PubMed    


  157. ZHENG MM, Wu YL
    "Tumor-free survival" Does Not Outweigh the Adverse Effects of Anti-EGFR Therapy and Chemotherapy in Patients With NSCLC.
    J Thorac Oncol. 2024;19:1146-1150.
    PubMed    


  158. LAISAAR T, Innos K, Jaal J, Oselin K, et al
    Lung Cancer in Estonia.
    J Thorac Oncol. 2024;19:1138-1145.
    PubMed    


  159. WOODARD GA, Jablons DM
    Shades of Gray: Do Never Smokers Benefit From Lung Cancer Screening Programs?
    J Thorac Oncol. 2024;19:1135-1137.
    PubMed    


  160. TURK MA
    Editorial Comment: Validation Study for the N Descriptor of the Newly Proposed 9th Edition of the TNM Staging System Proposed by the International Association for the Study of Lung Cancer.
    J Thorac Oncol. 2024;19:1133-1134.
    PubMed    


  161. PERRONE F, Leonetti A, Tiseo M, Facchinetti F, et al
    Benefit With No Target: Long-Term Outcomes of Chemoimmunotherapy in "PD-L1 Negative" NSCLC.
    J Thorac Oncol. 2024;19:1128-1132.
    PubMed    


  162. GRAY SG, Mutti L, Meirson T
    Encouraging Fussy Eaters in EGFR-Mutated Lung Cancer.
    J Thorac Oncol. 2024;19:1125-1127.
    PubMed    


  163. HU LY, Zhuang WT, Chen MJ, Liao J, et al
    EGFR Oncogenic Mutations in NSCLC Impair Macrophage Phagocytosis and Mediate Innate Immune Evasion Through Up-Regulation of CD47.
    J Thorac Oncol. 2024;19:1186-1200.
    PubMed     Abstract available


  164. WOLF AS, Eisele M, Giroux DJ, Gill R, et al
    The International Association for the Study of Lung Cancer Pleural Mesothelioma Staging Project: Expanded Database to Inform Revisions in the Ninth Edition of the TNM Classification of Pleural Mesothelioma.
    J Thorac Oncol. 2024;19:1242-1252.
    PubMed     Abstract available


    July 2024
  165. VAN ROSSUM PSN, Wolfhagen N, van Bockel LW, Coremans IEM, et al
    Real-world acute toxicity and 90-day mortality in patients with stage I non-small cell lung cancer treated with stereotactic body radiotherapy.
    J Thorac Oncol. 2024 Jul 25:S1556-0864(24)00684.
    PubMed     Abstract available


  166. JENSEN SO, Moore DA, Surani AA, Crosbie PA, et al
    Second Primary Lung Cancer - an emerging issue in lung cancer survivors.
    J Thorac Oncol. 2024 Jul 24:S1556-0864(24)00683.
    PubMed     Abstract available


  167. GRAY JE, Markovets A, Reungwetwattana T, Majem M, et al
    Longitudinal Analyses of Circulating-Tumor DNA for Detection of EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer Progression During Treatment: Data From FLAURA and AURA3.
    J Thorac Oncol. 2024 Jul 17:S1556-0864(24)00676.
    PubMed     Abstract available


  168. JUN S, Shukla NA, Durm G, Hui AB, et al
    Analysis of Circulating Tumor DNA Predicts Outcomes of Short Course Consolidation Immunotherapy in Unresectable Stage III Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2024 Jul 4:S1556-0864(24)00664.
    PubMed     Abstract available


  169. LIN YL, Wang GS, Wei JC
    Rheumatoid Arthritis and Risk of Lung Cancer.
    J Thorac Oncol. 2024;19:e15-e16.
    PubMed    


  170. YANG JJ, Wen W, Zheng W, Shu XO, et al
    "Some Thoughts on Lung Cancer Risk Prediction Models for Long-Term Smokers in Asia".
    J Thorac Oncol. 2024;19:e14-e15.
    PubMed    


  171. SHEN LT, Chen HL
    Some Thoughts on Lung Cancer Risk Prediction Models for Long-Term Smokers in Asia.
    J Thorac Oncol. 2024;19:e13-e14.
    PubMed    


  172. AFRIYIE-MENSAH JS, Dadzie MA, Vanderpuye VDNK, Calys-Tagoe B, et al
    Lung Cancer in Ghana.
    J Thorac Oncol. 2024;19:966-972.
    PubMed    


  173. MOCHIZUKI A, Shiraishi K, Honda T, Higashiyama RI, et al
    Passive Smoking-Induced Mutagenesis as a Promoter of Lung Carcinogenesis.
    J Thorac Oncol. 2024;19:984-994.
    PubMed     Abstract available


    June 2024
  174. SPICER JD, Cascone T, Wynes MW, Ahn MJ, et al
    Neoadjuvant and Adjuvant Treatment for Early-Stage Resectable Non-small Cell Lung Cancer (NSCLC): Consensus Recommendations from the International Association for the Study of Lung Cancer (IASLC).
    J Thorac Oncol. 2024 Jun 18:S1556-0864(24)00627.
    PubMed     Abstract available


  175. HSU CK, Lai CC
    Association Between Rheumatoid Arthritis and the Risk of Lung Cancer.
    J Thorac Oncol. 2024;19:e9.
    PubMed    


  176. URBANSKA EM, Sorensen JB, Santoni-Rugiu E
    Finding One Treatment for All Advanced EGFR-positive NSCLC-An Infinite Task.
    J Thorac Oncol. 2024;19:e11-e12.
    PubMed    


  177. CHO MH, Cho JH, Shin DW
    In Response.
    J Thorac Oncol. 2024;19:e10.
    PubMed    


  178. RICCIUTI B, Garassino MC
    Precision Immunotherapy for STK11/KEAP1-Mutant NSCLC.
    J Thorac Oncol. 2024;19:877-882.
    PubMed    


  179. DICKHOFF C, Heineman DJ, van Dorp M, Senan S, et al
    The Surgical Resection Difficulty From Neoadjuvant Chemoimmunotherapy Is Minimal and Neoadjuvant Therapy Should Be the Standard.
    J Thorac Oncol. 2024;19:862-865.
    PubMed    


  180. UGALDE FIGUEROA P, Lacroix V, Van Schil PE
    Neoadjuvant Chemoimmunotherapy Complicates Subsequent Surgical Resection and Adjuvant Immunotherapy Is Preferable From the Surgical Standpoint.
    J Thorac Oncol. 2024;19:858-861.
    PubMed    


  181. LI MS, Ou SI
    Iruplinalkib (WX-0593), the Seventh ALK Tyrosine Kinase Inhibitor Approved in People's Republic of China With More to Come.
    J Thorac Oncol. 2024;19:855-857.
    PubMed    


  182. PECCATORI FA, Florez N, Imbimbo M
    From Approximation to Precision: Fertility and Pregnancy Questions in Young Patients With Lung Cancer.
    J Thorac Oncol. 2024;19:852-854.
    PubMed    


    May 2024
  183. ROCCO G, Pennazza G, Tan KS, Vanstraelen S, et al
    A real-world assessment of stage I lung cancer through electronic nose technology.
    J Thorac Oncol. 2024 May 16:S1556-0864(24)00211.
    PubMed     Abstract available


  184. BILLE A, Ripley RT, Giroux DJ, Gill RR, et al
    The International Association for the Study of Lung Cancer Mesothelioma Staging Project: Proposals for the "N" Descriptors in the Forthcoming Ninth Edition of the TNM Classification for Pleural Mesothelioma.
    J Thorac Oncol. 2024 May 9:S1556-0864(24)00208.
    PubMed     Abstract available


  185. NOWAK AK, Giroux DJ, Eisele M, Rosenthal A, et al
    The International Association for the Study of Lung Cancer Pleural Mesothelioma Staging Project: Proposal for Revision of the TNM Stage Groupings in the Forthcoming (Ninth) Edition of the TNM Classification for Pleural Mesothelioma.
    J Thorac Oncol. 2024 May 9:S1556-0864(24)00207.
    PubMed     Abstract available


  186. NASSAR AH, Kim SY, Adib E, Naqash AR, et al
    Response letter by Nassar et al.
    J Thorac Oncol. 2024;19:e7-e8.
    PubMed    


  187. CHEN CY, Wang GS, Wei JC
    Comment on "Consolidation Osimertinib Versus Durvalumab following Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC".
    J Thorac Oncol. 2024;19:e6-e7.
    PubMed    


  188. ZHAO B, Yao L, Ma W
    Osimertinib Versus Durvalumab Versus Observation After Chemoradiation in Unresectable EGFR-Mutant NSCLC.
    J Thorac Oncol. 2024;19:e5-e6.
    PubMed    


  189. SRINIVASALU VK, Patnaik RS, Kiong LS, Justin JS, et al
    Lung Cancer in Brunei Darussalam.
    J Thorac Oncol. 2024;19:698-705.
    PubMed    


  190. LI Y, Adusumilli PS, Chou TY, Kadota K, et al
    Pro: "Is Spread Through Air Spaces an In Vivo Phenomenon or an Inducible Artifact?".
    J Thorac Oncol. 2024;19:677-697.
    PubMed     Abstract available


  191. BLAAUWGEERS H, Dickhoff C, Pelosi G, Timens W, et al
    Con: "Is Spread Through Air Spaces an In Vivo Phenomenon or an Inducible Artifact?".
    J Thorac Oncol. 2024;19:671-676.
    PubMed    


  192. SHIH JY
    ERBB2 Amplification in NSCLC: How Many Faces?
    J Thorac Oncol. 2024;19:668-670.
    PubMed    


  193. ISHIKAWA S
    Artificial Intelligence Enhances NSCLC Care by Predicting Treatment Outcomes, Validating Neoadjuvant Therapies, and Improving Precision.
    J Thorac Oncol. 2024;19:666-667.
    PubMed    


  194. WOODARD GA, Dacic S
    Should the TNM Staging of NSCLC Evolve Beyond Anatomical Descriptors?
    J Thorac Oncol. 2024;19:663-665.
    PubMed    


  195. LUO J, Sanchez M, Lee E, Hertzler H, et al
    Initial Chemotherapy for Locally Advanced and Metastatic NUT Carcinoma.
    J Thorac Oncol. 2024;19:829-838.
    PubMed     Abstract available


  196. OU SI, Hagopian GG, Zhang SS, Nagasaka M, et al
    Comprehensive Review of ROS1 Tyrosine Kinase Inhibitors-Classified by Structural Designs and Mutation Spectrum (Solvent Front Mutation [G2032R] and Central beta-Sheet 6 [Cbeta6] Mutation [L2086F]).
    J Thorac Oncol. 2024;19:706-718.
    PubMed     Abstract available


    April 2024
  197. GADGEEL SM, Rodriguez-Abreu D, Halmos B, Garassino MC, et al
    Pembrolizumab Plus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With Programmed Cell Death Ligand 1 Tumor Proportion Score Less Than 1%: Pooled Analysis of Outcomes After 5 Years of Follow-Up.
    J Thorac Oncol. 2024 Apr 18:S1556-0864(24)00169.
    PubMed     Abstract available


  198. ERNST SM, van Marion R, Atmodimedjo PN, de Jonge E, et al
    Clinical utility of circulating tumor DNA in patients with advanced KRAS(G12C)-mutated non-small cell lung cancer treated with sotorasib.
    J Thorac Oncol. 2024 Apr 12:S1556-0864(24)00165.
    PubMed     Abstract available


  199. HORNE A, Harada K, Brown KD, Chua KLM, et al
    Treatment response biomarkers: working towards personalised radiotherapy for lung cancer.
    J Thorac Oncol. 2024 Apr 12:S1556-0864(24)00164.
    PubMed     Abstract available


  200. KIM IH, Lee GD, Choi S, Kim HR, et al
    Validation Study for the N Descriptor of the Newly Proposed 9th Edition of the TNM Staging System Proposed by the International Association for the Study of Lung Cancer.
    J Thorac Oncol. 2024 Apr 11:S1556-0864(24)00160.
    PubMed     Abstract available


  201. SHUKLA V, Wang H, Varticovski L, Baek S, et al
    Genome-wide Analysis Identifies Nuclear Factor 1C as a Novel Transcription Factor and Potential Therapeutic Target in Small Cell Lung Cancer.
    J Thorac Oncol. 2024 Apr 5:S1556-0864(24)00131.
    PubMed     Abstract available


  202. DETTERBECK FC, Ostrowski M, Hoffmann H, Rami-Porta R, et al
    The IASLC Lung Cancer Staging Project: Proposals for Revision of the Classification of Residual Tumor after Resection for the Forthcoming (9(th)) Edition of the TNM Classification of Lung Cancer.
    J Thorac Oncol. 2024 Apr 1:S1556-0864(24)00129.
    PubMed     Abstract available


  203. CHANG CL, Lin KC, Chen WM, Shia BC, et al
    Correspondence: Intensity-Modulated Proton Therapy Versus Intensity-Modulated Radiotherapy for Inoperable Esophageal Squamous Cell Carcinoma: Methodologic Issues.
    J Thorac Oncol. 2024;19:e2-e4.
    PubMed    


  204. CHIOU CC, Lai TY
    Intensity-Modulated Proton Therapy Versus Intensity-Modulated Radiotherapy for Inoperable Esophageal Squamous Cell Carcinoma: Methodologic Issues.
    J Thorac Oncol. 2024;19:e1-e2.
    PubMed    


  205. SMESSEIM I, Baas P
    Immunotherapy Is a Good Standard Option for Patients With Malignant Pleural Mesothelioma, Despite the Real-World Results From Australia.
    J Thorac Oncol. 2024;19:547-550.
    PubMed    


  206. GRAY SG, Meirson T, Mutti L
    Based on the Real-World Results From Australia, Immunotherapy Is Not a Good Option for Patients With Mesothelioma.
    J Thorac Oncol. 2024;19:541-546.
    PubMed    


  207. SAIFO M, Alali M, Alhabeb H, Awak M, et al
    Lung Cancer in Syria.
    J Thorac Oncol. 2024;19:534-540.
    PubMed    


  208. SHOENBILL KA, Goldstein AO
    Better Together: Advancing Tobacco Use Treatment and Lung Cancer Screening.
    J Thorac Oncol. 2024;19:531-533.
    PubMed    


  209. ZHU Z, Chen H
    Additional Evidence for Postoperative Radiation Therapy on Thymic Carcinoma.
    J Thorac Oncol. 2024;19:528-530.
    PubMed    


  210. LEE JB, Nagasaka M
    Translational Research in ROS1-Positive NSCLC: Are We Moving Out of the Six Blind Men and the Elephant Stage?
    J Thorac Oncol. 2024;19:525-527.
    PubMed    


  211. LEONG TL, McWilliams A, Wright GM
    Incidental Pulmonary Nodules: An Opportunity to Complement Lung Cancer Screening.
    J Thorac Oncol. 2024;19:522-524.
    PubMed    


  212. DWYER LJ, Singhal N, Yu B, Kao S, et al
    Successful Osimertinib Rechallenge After Relapse Following Adjuvant Osimertinib: A Case Report.
    J Thorac Oncol. 2024;19:650-652.
    PubMed     Abstract available


  213. RIMNER A, Ahmad U, Lobaugh SM, Zhang Z, et al
    Postoperative Radiation Therapy for Thymic Carcinoma: An Analysis of the International Thymic Malignancy Interest Group/European Society of Thoracic Surgeons Database.
    J Thorac Oncol. 2024;19:626-635.
    PubMed     Abstract available


  214. MCNAMEE N, Harvey C, Gray L, Khoo T, et al
    Brief Report: Real-World Toxicity and Survival of Combination Immunotherapy in Pleural Mesothelioma-RIOMeso.
    J Thorac Oncol. 2024;19:636-642.
    PubMed     Abstract available


  215. NEL AE, Pavlisko EN, Roggli VL
    The Interplay Between the Immune System, Tumor Suppressor Genes, and Immune Senescence in Mesothelioma Development and Response to Immunotherapy.
    J Thorac Oncol. 2024;19:551-564.
    PubMed     Abstract available


    March 2024
  216. TRAVIS WD, Eisele M, Nishimura KK, Aly R, et al
    The IASLC Lung Cancer Staging Project: Recommendation to Introduce Spread Through Air Spaces (STAS) as a Histologic Descriptor in the 9(th) Edition of the TNM Classification of Lung Cancer.Analysis of 4,061 Pathologic Stage I Non-Small cell Lung Carci
    J Thorac Oncol. 2024 Mar 18:S1556-0864(24)00122.
    PubMed     Abstract available


  217. BORGEAUD M, Parikh K, Banna GL, Kim F, et al
    Unveiling the Landscape of uncommon EGFR Mutations in Non-Small Cell Lung Cancer - A Systematic Review.
    J Thorac Oncol. 2024 Mar 16:S1556-0864(24)00123.
    PubMed     Abstract available


  218. HINES JB, Cameron RB, Esposito A, Kim L, et al
    Evaluation of MPR and pCR as surrogate endpoints for survival in randomized controlled trials of neoadjuvant immune checkpoint blockade in resectable in non-small cell lung cancer.
    J Thorac Oncol. 2024 Mar 8:S1556-0864(24)00117.
    PubMed     Abstract available


  219. CHENG Y, Fan Y, Zhao Y, Huang D, et al
    Tislelizumab Plus Platinum and Etoposide Versus Placebo Plus Platinum and Etoposide as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer (RATIONALE-312): a Multicenter, Double-Blind, Placebo-Controlled, Randomized, Phase 3 Clinical Trial
    J Thorac Oncol. 2024 Mar 7:S1556-0864(24)00115.
    PubMed     Abstract available


  220. RAMI-PORTA R, Nishimura KK, Giroux DJ, Detterbeck F, et al
    The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groups in the Forthcoming (Ninth) Edition of the TNM Classification for Lung Cancer.
    J Thorac Oncol. 2024 Mar 4:S1556-0864(24)00079.
    PubMed     Abstract available


  221. KIM BG, Yoon S, Lee SY, Sohn JW, et al
    How Does Rheumatoid Arthritis Increase the Risk of Lung Cancer?
    J Thorac Oncol. 2024;19:509-510.
    PubMed    


  222. WERNER RS, Curioni-Fontecedro A, Mauti LA, Addeo A, et al
    Lung Cancer in Switzerland.
    J Thorac Oncol. 2024;19:385-394.
    PubMed    


  223. TEN HAAF K
    Considerations for Enhancing Lung Cancer Risk Prediction and Screening in Asian Populations.
    J Thorac Oncol. 2024;19:373-375.
    PubMed    


  224. LI CP, Tsai RY, Chang HC, Gau SY, et al
    Survival and Prognosis After Carbon-Ion Radiotherapy in Patients With NSCLC.
    J Thorac Oncol. 2024;19:507-508.
    PubMed    


  225. CHEN LN, Lee ATM, Nagasaka M, Ou SI, et al
    Chemotherapy and Osimertinib Combination Should Be the First-Line Treatment for All Advanced EGFR+ NSCLC.
    J Thorac Oncol. 2024;19:380-384.
    PubMed    


  226. LIM SM, Lee JB, Cho BC
    Chemotherapy and Osimertinib Combination Should Not Be the First-Line Treatment for All Advanced EGFR+ NSCLC.
    J Thorac Oncol. 2024;19:376-379.
    PubMed    


  227. YALAMANCHALI A, Hassan KA
    MUC1-C: The Occam Razor of Osimertinib Resistance?
    J Thorac Oncol. 2024;19:370-372.
    PubMed    


  228. DAMMEIJER F, Dumoulin DW, Aerts JGJV
    Anti-Vascular Endothelial Growth Factor/Programmed Cell Death Protein 1 Bispecific Antibodies: Using Nunchucks to Fight an Old Adversary.
    J Thorac Oncol. 2024;19:366-369.
    PubMed    


  229. CANI M, Novello S, Bironzo P
    Mismatch Repair Deficiency in Lung Tumors: Adding a New Layer of Complexity on Pie Slices.
    J Thorac Oncol. 2024;19:363-365.
    PubMed    


  230. BORCZUK AC
    Invasive Size in Lung Adenocarcinoma-Reproducible Criteria, More Accurate Staging.
    J Thorac Oncol. 2024;19:360-362.
    PubMed    


  231. YANG SR, Gedvilaite E, Ptashkin R, Chang J, et al
    Microsatellite Instability and Mismatch Repair Deficiency Define a Distinct Subset of Lung Cancers Characterized by Smoking Exposure, High Tumor Mutational Burden, and Recurrent Somatic MLH1 Inactivation.
    J Thorac Oncol. 2024;19:409-424.
    PubMed     Abstract available


    February 2024
  232. FONG KM, Rosenthal A, Giroux DJ, Nishimura KK, et al
    The IASLC Lung Cancer Staging Project: Proposals for the Revision of the M Descriptors in the Forthcoming 9th edition of the TNM Classification of Lung Cancer.
    J Thorac Oncol. 2024 Feb 4:S1556-0864(24)00060.
    PubMed     Abstract available


  233. ZHOU RX, Liao HJ, Hu JJ, Xiong H, et al
    Global burden of lung cancer attributable to household fine particulate matter pollution in 204 countries and territories, 1990-2019.
    J Thorac Oncol. 2024 Feb 2:S1556-0864(24)00034.
    PubMed     Abstract available


  234. TORASAWA M, Horinouchi H
    A Response to the Letter to the Editor: "A Paradigm Shift in First-Line Treatment Can Have Many Implications for Second-Line Treatment".
    J Thorac Oncol. 2024;19:351-352.
    PubMed    


  235. NISHIMURA T
    A Paradigm Shift in First-Line Treatment Can Have Many Implications For Second-Line Treatment.
    J Thorac Oncol. 2024;19:350.
    PubMed    


  236. HORITA N, Takase-Minegishi K
    Information Bias Might Exaggerate Lung Cancer Risk of Patients With Rheumatoid Arthritis.
    J Thorac Oncol. 2024;19:348.
    PubMed    


  237. CHANG HC, Gau SY
    Real-World Evidence of the Association Between Rheumatoid Arthritis and Lung Cancer.
    J Thorac Oncol. 2024;19:346.
    PubMed    


  238. YUAN C, Huang R, Wang Y
    An Error in Modeling and the Selection of Independent Radiomics Variables Need Caution.
    J Thorac Oncol. 2024;19:344-345.
    PubMed    


  239. BERMAS BL, Gerber DE
    The Joint Problem of Rheumatoid Arthritis and Lung Cancer.
    J Thorac Oncol. 2024;19:196-198.
    PubMed    


  240. VOKES EE, Mornex F, Sezer A, Cheng Y, et al
    Bintrafusp Alfa With CCRT Followed by Bintrafusp Alfa Versus Placebo With CCRT Followed by Durvalumab in Patients With Unresectable Stage III NSCLC: A Phase 2 Randomized Study.
    J Thorac Oncol. 2024;19:285-296.
    PubMed     Abstract available


  241. REMON J, Saw SPL, Cortiula F, Singh PK, et al
    Perioperative Treatment Strategies in EGFR-Mutant Early-Stage NSCLC: Current Evidence and Future Challenges.
    J Thorac Oncol. 2024;19:199-215.
    PubMed     Abstract available


  242. DACIC S, Cao X, Bota-Rabassedas N, Sanchez-Espiridion B, et al
    Genomic Staging of Multifocal Lung Squamous Cell Carcinomas Is Independent of the Comprehensive Morphologic Assessment.
    J Thorac Oncol. 2024;19:273-284.
    PubMed     Abstract available


  243. OWONIKOKO TK
    SCLC Classification by Platinum Sensitivity in the Era of Immunotherapy: Mere Relic or a Valuable Treasure to Keep?
    J Thorac Oncol. 2024;19:193-195.
    PubMed    


  244. LE X
    Partners in Crime: Co-Occurring Genetic Alterations in EGFR-Mutant NSCLC.
    J Thorac Oncol. 2024;19:190-192.
    PubMed    


  245. LEE JH
    Is Real-World Evidence on Acquired Resistance to Osimertinib Relevant Clinically?
    J Thorac Oncol. 2024;19:187-189.
    PubMed    


  246. SHIRAISHI Y, Tokito T, Toyozawa R, Inagaki C, et al
    Five Cases of Cytokine Release Syndrome in Patients Receiving Cytotoxic Chemotherapy Together With Nivolumab Plus Ipilimumab: A Case Report.
    J Thorac Oncol. 2024;19:337-343.
    PubMed     Abstract available


    January 2024
  247. SHI Y, Hu X, Li X, Gong C, et al
    Ficonalkib (SY-3505) in Advanced ALK-Positive Non-Small-Cell Lung Cancer: A Multicenter, Open-Label, Single-Arm, Phase I/? Study.
    J Thorac Oncol. 2024 Jan 29:S1556-0864(24)00035.
    PubMed     Abstract available


  248. SHI Y, Chen J, Yang R, Wu H, et al
    Iruplinalkib (WX-0593) versus crizotinib in ALK TKI-naive locally advanced or metastatic ALK-positive non-small cell lung cancer: interim analysis of a randomized, open-label, phase III study (INSPIRE).
    J Thorac Oncol. 2024 Jan 25:S1556-0864(24)00033.
    PubMed     Abstract available


  249. NASSAR AH, Kim SY, Aredo JV, Feng J, et al
    Consolidation Osimertinib versus Durvalumab versus Observation following Concurrent Chemoradiation in Unresectable EGFR-Mutant Non-Small-Cell Lung Cancer: A Multicenter Retrospective Cohort Study.
    J Thorac Oncol. 2024 Jan 24:S1556-0864(24)00032.
    PubMed     Abstract available


  250. SIMONS E, Camidge DR
    Lung cancer oncogene-directed therapy, fertility and pregnancy.
    J Thorac Oncol. 2024 Jan 5:S1556-0864(24)00023.
    PubMed     Abstract available


  251. YU S, Feng J
    Comment on "Durvalumab After Sequential Chemoradiotherapy in Stage III, Unresectable NSCLC: The Phase 2 PACIFIC-6 Trial".
    J Thorac Oncol. 2024;19:173-174.
    PubMed    


  252. TANIZAKI J, Hayashi H
    Unraveling Pseudo Kidney Injury: The Significance of Understanding Our "MATE" in Molecular-Targeted Therapies.
    J Thorac Oncol. 2024;19:15-17.
    PubMed    


  253. BATAH H, Majeed Z, Moudgil R
    Tale of Two Cs: Inter-Relationship Between Cardiovascular and Lung Cancer.
    J Thorac Oncol. 2024;19:13-14.
    PubMed    


  254. SINGHAL S, Gandara D, Riess JW
    Mapping EGFR Exon 20 Resistance Mutations: An Intricate Landscape.
    J Thorac Oncol. 2024;19:10-12.
    PubMed    


  255. FANG W, Girard N, Cilento V, Goren E, et al
    The International Association for the Study of Lung Cancer Thymic Epithelial Tumors Staging Project: Proposals for the N and the M Components for the Forthcoming (Ninth) Edition of the TNM Classification of Malignant Tumors.
    J Thorac Oncol. 2024;19:52-70.
    PubMed     Abstract available


  256. CHEN MF, Harada G, Liu D, DeMatteo R, et al
    Brief Report: Tyrosine Kinase Inhibitors for Lung Cancers That Inhibit MATE-1 Can Lead to "False" Decreases in Renal Function.
    J Thorac Oncol. 2024;19:153-159.
    PubMed     Abstract available


  257. UDAGAWA H, Nilsson MB, Robichaux JP, He J, et al
    HER4 and EGFR Activate Cell Signaling in NRG1 Fusion-Driven Cancers: Implications for HER2-HER3-specific Versus Pan-HER Targeting Strategies.
    J Thorac Oncol. 2024;19:106-118.
    PubMed     Abstract available


  258. HAMADA A, Suda K, Nishino M, Obata K, et al
    Secondary Mutations of the EGFR Gene That Confer Resistance to Mobocertinib in EGFR Exon 20 Insertion.
    J Thorac Oncol. 2024;19:71-79.
    PubMed     Abstract available


  259. LAM S, Wynes MW, Connolly C, Ashizawa K, et al
    The International Association for the Study of Lung Cancer Early Lung Imaging Confederation Open-Source Deep Learning and Quantitative Measurement Initiative.
    J Thorac Oncol. 2024;19:94-105.
    PubMed     Abstract available


  260. TAGLIAMENTO M, Di Maio M, Remon J, Bironzo P, et al
    Meta-Analysis on the Combination of Chemotherapy With Programmed Death-Ligand 1 and Programmed Cell Death Protein 1 Blockade as First-Line Treatment for Unresectable Pleural Mesothelioma.
    J Thorac Oncol. 2024;19:166-172.
    PubMed     Abstract available


    December 2023
  261. YANG JC, Han B, De La Mora Jimenez E, Lee JS, et al
    Pembrolizumab With or Without Lenvatinib for First-Line Metastatic Non?Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score >/=1% (LEAP-007): A Randomized, Double-Blind, Phase 3 Trial.
    J Thorac Oncol. 2023 Dec 28:S1556-0864(23)02432.
    PubMed     Abstract available


  262. ODINTSOV I, Makarem M, Nishino M, Bachert SE, et al
    Prevalence and Therapeutic Targeting of High Level ERBB2 Amplification in Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2023 Dec 26:S1556-0864(23)02428.
    PubMed     Abstract available


  263. BISCHOFF P, Reck M, Overbeck T, Christopoulos P, et al
    Outcome of first-line treatment with pembrolizumab according to KRAS/TP53 mutational status for non-squamous PD-L1 high (>/=50%) NSCLC in the German National Network Genomic Medicine Lung Cancer (nNGM).
    J Thorac Oncol. 2023 Dec 12:S1556-0864(23)02423.
    PubMed     Abstract available


  264. VAN SCHIL PE, Asamura H, Nishimura KK, Rami-Porta R, et al
    The IASLC Lung Cancer Staging Project: Proposals for the Revisions of the T Descriptors in the Forthcoming Ninth Edition of the TNM Classification for Lung Cancer.
    J Thorac Oncol. 2023 Dec 7:S1556-0864(23)02411.
    PubMed     Abstract available


  265. LI W, Fei K, Guo L, Wang Y, et al
    CD74/SLC34A2-ROS1 fusion variants involving the transmembrane region predict poor response to crizotinib in non-small cell lung cancer independent of TP53 mutations.
    J Thorac Oncol. 2023 Dec 7:S1556-0864(23)02414.
    PubMed     Abstract available


  266. DACIC S, Travis WD, Giltnane JM, Kos F, et al
    Artificial intelligence-powered assessment of pathologic response to neoadjuvant atezolizumab in patients with non-small cell lung cancer: results from the LCMC3 study.
    J Thorac Oncol. 2023 Dec 7:S1556-0864(23)02415.
    PubMed     Abstract available


  267. XHEMALAJ D, Gradica F, Skenduli I, Tula J, et al
    Lung Cancer in Albania.
    J Thorac Oncol. 2023;18:1632-1637.
    PubMed    


  268. FERREIRA M, Redman MW, Reckamp KL
    Moving Toward Rationale Phase 3 Designs for Advanced NSCLC.
    J Thorac Oncol. 2023;18:1629-1631.
    PubMed    


  269. LI Z, Lu S
    Third-Generation EGFR Tyrosine Kinase Inhibitor for Central Nervous System Metastases EGFR-Mutant NSCLC: Current Evidence and Future Perspectives.
    J Thorac Oncol. 2023;18:1625-1628.
    PubMed    


  270. MAKAREM M, Rotow JK
    Genotype Versus Phenotype: Defining Predictive Biomarkers of Immunotherapy Response.
    J Thorac Oncol. 2023;18:1615-1617.
    PubMed    


  271. RUFFINI E, Huang J, Cilento V, Goren E, et al
    The International Association for the Study of Lung Cancer Thymic Epithelial Tumors Staging Project: Proposal for a Stage Classification for the Forthcoming (Ninth) Edition of the TNM Classification of Malignant Tumors.
    J Thorac Oncol. 2023;18:1655-1671.
    PubMed     Abstract available


  272. MAROM EM, Fang W, Ruffini E, Detterbeck F, et al
    The International Association for the Study of Lung Cancer Thymic Epithelial Tumor Staging Project: A Re-Assessment of the International Thymic Malignancy Interest Group/International Association for the Study of Lung Cancer Lymph Node Map for Thymic
    J Thorac Oncol. 2023;18:1672-1688.
    PubMed     Abstract available


  273. OKUMURA M, Marino M, Cilento V, Goren E, et al
    The International Association for the Study of Lung Cancer Thymic Epithelial Tumor Staging Project: Proposal for the T Component for the Forthcoming (Ninth) Edition of the TNM Classification of Malignant Tumors.
    J Thorac Oncol. 2023;18:1638-1654.
    PubMed     Abstract available


  274. ANG YLE, Soo RA
    Has the Ship Sailed on Second-Generation ALK Tyrosine Kinase Inhibitors in the Post-Crizotinib Setting?
    J Thorac Oncol. 2023;18:1621-1624.
    PubMed    


  275. MEDINA CG, Xu Y, Ripley RT
    International Prognostic Modeling: A Platform for Collaborative Approach for Patients With Mesothelioma.
    J Thorac Oncol. 2023;18:1618-1620.
    PubMed    


  276. SOO RA, Cho BC, Kim JH, Ahn MJ, et al
    Central Nervous System Outcomes of Lazertinib Versus Gefitinib in EGFR-Mutated Advanced NSCLC: A LASER301 Subset Analysis.
    J Thorac Oncol. 2023;18:1756-1766.
    PubMed     Abstract available


  277. WOLF AS, Rosenthal A, Giroux DJ, Nowak AK, et al
    The International Association for the Study of Lung Cancer Pleural Mesothelioma Staging Project: Updated Modeling of Prognostic Factors in Pleural Mesothelioma.
    J Thorac Oncol. 2023;18:1689-1702.
    PubMed     Abstract available


    November 2023
  278. WANG K, Du R, Myall NJ, Lewis WE, et al
    BRIEF REPORT: Real-world efficacy and safety of amivantamab for EGFR-mutant non-small cell lung cancer (NSCLC).
    J Thorac Oncol. 2023 Nov 25:S1556-0864(23)02376.
    PubMed     Abstract available


  279. O'LEARY CL, Pierce N, Patel SP, Naidoo J, et al
    Immune-Related Toxicity in Non-small cell Lung Cancer: Current State-of-The-Art and Emerging Clinical Challenges.
    J Thorac Oncol. 2023 Nov 25:S1556-0864(23)02374.
    PubMed     Abstract available


  280. LIAO W, Fehnel C, Goss J, Shepherd CJ, et al
    Incidentally-Detected Lung Cancer in Persons Too Young or Too Old for Lung Cancer Screening in a Mississippi Delta Cohort.
    J Thorac Oncol. 2023 Nov 18:S1556-0864(23)02371.
    PubMed     Abstract available


  281. LU C, Wei XW, Wang Z, Zhou Z, et al
    Allelic context of EGFR C797X mutant lung cancer defines four subtypes with heterogeneous genomic landscape and distinct clinical outcomes.
    J Thorac Oncol. 2023 Nov 17:S1556-0864(23)02372.
    PubMed     Abstract available


  282. HENSCHKE C, Huber R, Jiang L, Yang D, et al
    Perspective on Management of LDCT Findings on Low-Dose Computed Tomography Examinations for Lung Cancer Screening From the IASLC Early Detection & Screening Committee.
    J Thorac Oncol. 2023 Nov 16:S1556-0864(23)02369.
    PubMed     Abstract available


  283. GULATI S, Ivic-Pavlicic T, Joasil J, Flores R, et al
    Outcomes in Incidentally Versus Screening Detected Stage I Lung Cancer Surgery Patients.
    J Thorac Oncol. 2023 Nov 15:S1556-0864(23)02364.
    PubMed     Abstract available


  284. CARTMEL B, Fucito LM, Bold KW, Neveu S, et al
    No Additional Effect of a Personalized Tobacco Treatment Intervention on Smoking Abstinence in Individuals Eligible for Lung Cancer Screening: Brief Report of a Randomized Trial.
    J Thorac Oncol. 2023 Nov 15:S1556-0864(23)02368.
    PubMed     Abstract available


  285. YANG JJ, Wen W, Zahed H, Zheng W, et al
    Lung Cancer Risk Prediction Models for Asian Ever-Smokers.
    J Thorac Oncol. 2023 Nov 7:S1556-0864(23)02352.
    PubMed     Abstract available


  286. KUBO N, Suefuji H, Nakajima M, Tokumaru S, et al
    Five-year survival outcomes after carbon-ion radiotherapy for operable stage I non-small cell lung cancer: a Japanese national registry study (J-CROS-LUNG).
    J Thorac Oncol. 2023 Nov 2:S1556-0864(23)02346.
    PubMed     Abstract available


  287. HARATAKE N, Ozawa H, Morimoto Y, Yamashita N, et al
    MUC1-C IS A COMMON DRIVER OF ACQUIRED OSIMERTINIB RESISTANCE IN NON-SMALL CELL LUNG CANCER.
    J Thorac Oncol. 2023 Nov 2:S1556-0864(23)02348.
    PubMed     Abstract available


  288. HONG TH, Hwang S, Cho J, Choi YL, et al
    Clinical Significance of the Proposed Pathologic Criteria for Invasion by the International Association for the Study of Lung Cancer in Resected Nonmucinous Lung Adenocarcinoma.
    J Thorac Oncol. 2023 Nov 2:S1556-0864(23)02311.
    PubMed     Abstract available


  289. QIU Z, Huang H, Zhang Y, Chen D, et al
    Comment on "Plasma Progastrin-Releasing Peptide and Chromogranin A Assays for Diagnosing and Monitoring Lung Well-Differentiated Neuroendocrine Tumors: A Brief Report".
    J Thorac Oncol. 2023;18:e138-e139.
    PubMed    


  290. LI A, Yang Y, Zhang L, Hong S, et al
    STK11/LKB1 and Immune Phenotypes Co-Determine Immunotherapy Outcomes.
    J Thorac Oncol. 2023;18:e135-e138.
    PubMed    


  291. AMORI G, Sugawara E, Inamura K
    Leveraging Transcriptomics Data to Refine Immunotherapy Response Prediction in NSCLC: STK11 Deficiency and Beyond.
    J Thorac Oncol. 2023;18:e134-e135.
    PubMed    


  292. CHEN WM, Yu YH, Chen M, Shia BC, et al
    Correspondence: The Causality Between Statin Use and Reduced Mortality of Esophageal Cancer Remains Unproven.
    J Thorac Oncol. 2023;18:e132-e134.
    PubMed    


  293. ZHANG Y, Dai K, He D, Chen Z, et al
    The Causality Between Statin Use and Reduced Mortality of Esophageal Cancer Remains Unproven.
    J Thorac Oncol. 2023;18:e130-e131.
    PubMed    


  294. NIU Y, Yao F, Yang H
    "Keaping" an Eye on the NRF2 Signature Score: Expanding Its Applicability in Lung Cancer.
    J Thorac Oncol. 2023;18:e126-e128.
    PubMed    


  295. MARTI JLG, Wells JZ, Wells A
    Statins as a Secondary Preventive Agent for Metastatic Cancer.
    J Thorac Oncol. 2023;18:e125-e126.
    PubMed    


  296. OKONTA KE, Baiyewu LA, Jimoh MA
    Lung Cancer in Nigeria.
    J Thorac Oncol. 2023;18:1446-1457.
    PubMed    


  297. DAGOGO-JACK I
    We Don't Talk (Enough) About BRAF.
    J Thorac Oncol. 2023;18:1443-1445.
    PubMed    


  298. LEE JB, Ou SI
    Plasma Genotyping From the CROWN, ALTA-1L, and ALEX Trials: Can We Speak With One Voice on What to Test, How to Test, When to Test, and for What Purpose?
    J Thorac Oncol. 2023;18:1434-1442.
    PubMed    


  299. HIJAZO-PECHERO S, Munoz-Pinedo C, Nadal E
    A Transcriptomic Approach Outperforms Mutational Analysis to Identify KEAP1/NFE2L2 Pathway Activation in Patients With NSCLC.
    J Thorac Oncol. 2023;18:1431-1433.
    PubMed    


  300. SOZZI G, Pastorino U
    Small RNAs Do It Better.
    J Thorac Oncol. 2023;18:1428-1430.
    PubMed    


  301. YANKELEVITZ DF, Yip R, Henschke CI
    Considerations for Incorporating Family History Into Low-dose Computed Tomography Screening Recommendations.
    J Thorac Oncol. 2023;18:1426-1427.
    PubMed    


  302. SAKAI T, Matsumoto S, Ueda Y, Shibata Y, et al
    Clinicogenomic Features and Targetable Mutations in NSCLCs Harboring BRAF Non-V600E Mutations: A Multi-Institutional Genomic Screening Study (LC-SCRUM-Asia).
    J Thorac Oncol. 2023;18:1538-1549.
    PubMed     Abstract available


  303. AHN MJ, Bondarenko I, Kalinka E, Cho BC, et al
    Durvalumab in Combination With Olaparib Versus Durvalumab Alone as Maintenance Therapy in Metastatic NSCLC: The Phase 2 ORION Study.
    J Thorac Oncol. 2023;18:1594-1606.
    PubMed     Abstract available


    October 2023
  304. WANG L, Luo Y, Ren S, Zhang Z, et al
    A phase Ib study of ivonescimab, a PD-1/VEGF bispecific antibody, as first- or second-line therapy for advanced or metastatic immunotherapy naive non-small-cell lung cancer.
    J Thorac Oncol. 2023 Oct 23:S1556-0864(23)02312.
    PubMed     Abstract available


  305. HUANG J, Osarogiagbon RU, Giroux DJ, Nishimura KK, et al
    The IASLC Lung Cancer Staging Project: Proposals for the Revision of the N Descriptors in the Forthcoming 9th Edition of the TNM Classification for Lung Cancer.
    J Thorac Oncol. 2023 Oct 20:S1556-0864(23)02310.
    PubMed     Abstract available


  306. CHO MH, Cho JH, Eun Y, Han K, et al
    Rheumatoid arthritis and risk of lung cancer: a nationwide cohort study.
    J Thorac Oncol. 2023 Oct 12:S1556-0864(23)02293.
    PubMed     Abstract available


  307. STOCKHAMMER P, Grant M, Wurtz A, Foggetti G, et al
    Co-occurring Alterations in Multiple Tumor Suppressor Genes are Associated with Worse Outcomes in Patients with EGFR-mutant Lung Cancer.
    J Thorac Oncol. 2023 Oct 6:S1556-0864(23)02264.
    PubMed     Abstract available


  308. HENSCHKE CI, Yip R, Sun Q, Li P, et al
    Prospective Cohort Study to Compare Long-term Lung Cancer-Specific and All-Cause Survival of Clinical Early Stage (T1a-b;
    J Thorac Oncol. 2023 Oct 6:S1556-0864(23)02265.
    PubMed     Abstract available


  309. ROTOW JK, Lee JK, Madison RW, Oxnard GR, et al
    Real-world genomic profile of EGFR second-site mutations and other osimertinib resistance mechanisms, and clinical landscape of non-small cell lung cancer (NSCLC) post-osimertinib.
    J Thorac Oncol. 2023 Oct 6:S1556-0864(23)02263.
    PubMed     Abstract available


  310. TRIPHURIDET N, Gao Y, Ou SI
    Reply to Jayaraj et al. "Clinical Validity and Conceptual Interpretation of the Meta-Analysis on the Efficacy of LDCT Lung Cancer Screening in Never-Smokers".
    J Thorac Oncol. 2023;18:e122-e123.
    PubMed    


  311. JAYARAJ R, Shetty S, Ilankumaran S, Merchant Y, et al
    Clinical Validity and Conceptual Interpretation of Low-Dose Computed Tomography Screening in Asian Female Never-Smokers Are as Efficacious in Detecting Lung Cancer as in Asian Male Ever-Smokers.
    J Thorac Oncol. 2023;18:e118-e122.
    PubMed    


  312. CHOUR A, Duruisseaux M
    Response to Commentary on "Brief Report: Severe Sotorasib-Related Hepatotoxicity and Non-Liver Adverse Events Associated With Sequential Anti-PD(L)1 and Sotorasib Therapy in KRASG12C-Mutant Lung Cancer".
    J Thorac Oncol. 2023;18:e114-e115.
    PubMed    


  313. DETTERBECK FC, Asamura H, Rami-Porta R, Rusch VW, et al
    The Only Constant Is Change: Introducing the International Association for the Study of Lung Cancer Proposals for the Ninth Edition of TNM Stage Classification of Thoracic Tumors.
    J Thorac Oncol. 2023;18:1258-1260.
    PubMed    


  314. INAMURA K
    Exploiting Tumor Immune Microenvironment to Predict Response to Immunotherapy Plus Chemotherapy in NSCLC.
    J Thorac Oncol. 2023;18:e109-e110.
    PubMed    


  315. ADJEI AA
    The Coming of a New Age: The Journal of Thoracic Oncology Goes Electronic in 2024.
    J Thorac Oncol. 2023;18:1257.
    PubMed    


  316. HOE HJ, Balasubramanian A, John T
    LASERing FLAURAL Arrangements in Asian EGFR Subsets.
    J Thorac Oncol. 2023;18:1261-1264.
    PubMed    


  317. REUNGWETWATTANA T, Cho BC, Lee KH, Pang YK, et al
    Lazertinib Versus Gefitinib Tyrosine Kinase Inhibitors in Treatment-Naive Patients With EGFR-Mutated Advanced NSCLC: Analysis of the Asian Subpopulation in LASER301.
    J Thorac Oncol. 2023;18:1351-1361.
    PubMed     Abstract available


  318. PEARSALL SM, Williamson SC, Humphrey S, Hughes E, et al
    Lineage Plasticity in SCLC Generates Non-Neuroendocrine Cells Primed for Vasculogenic Mimicry.
    J Thorac Oncol. 2023;18:1362-1385.
    PubMed     Abstract available


  319. GELSOMINO F, Vitale G, Raschi E, Ardizzoni A, et al
    Severe Liver Injury Triggered by Sequential Use of Immune Checkpoint Blockers and Tyrosine Kinase Inhibitors: An Emerging Clinical Issue.
    J Thorac Oncol. 2023;18:e112-e113.
    PubMed    


  320. CHEN WM, Yu YH, Chen M, Shia BC, et al
    Correspondence: Statin Use During Concurrent Chemoradiotherapy With Improved Survival Outcomes in Esophageal Squamous Cell Carcinoma.
    J Thorac Oncol. 2023;18:e107-e109.
    PubMed    


  321. LIN TA, Chen SY, Chang R, Sun CK, et al
    Correspondence: Statin Use During Concurrent Chemoradiotherapy With Improved Survival Outcomes in Esophageal Squamous Cell Carcinoma: A Propensity Score-Matched Nationwide Cohort Study.
    J Thorac Oncol. 2023;18:e105-e106.
    PubMed    


  322. WRIGHT K, Digby GC, Gyawali B, Jad R, et al
    Malignant Superior Vena Cava Syndrome: A Scoping Review.
    J Thorac Oncol. 2023;18:1268-1276.
    PubMed     Abstract available


    September 2023
  323. DUAN J, Wu L, Yang K, Zhao J, et al
    Safety, tolerability, pharmacokinetics, and preliminary efficacy of YK-029A in treatment-naive patients with advanced non-small cell lung cancer harboring EGFR exon 20 insertion mutations: A phase I trial.
    J Thorac Oncol. 2023 Sep 28:S1556-0864(23)02259.
    PubMed     Abstract available


  324. RECK M, Barlesi F, Chih-Hsin Yang J, Westeel V, et al
    Avelumab vs platinum-based doublet chemotherapy as first-line treatment for patients with high-expression PD-L1+ metastatic non-small cell lung cancer: primary analysis from the phase 3 JAVELIN Lung 100 trial.
    J Thorac Oncol. 2023 Sep 23:S1556-0864(23)02250.
    PubMed     Abstract available


  325. JIANG C, Zhang Y, Fu F, Deng P, et al
    A Shift in Paradigm: Selective Lymph Node Dissection for Minimizing Oversurgery in Early-Stage Lung Cancer.
    J Thorac Oncol. 2023 Sep 23:S1556-0864(23)02245.
    PubMed     Abstract available


  326. TORASAWA M, Horinouchi H, Nomura S, Igawa S, et al
    Reconsidering the cutoff value for sensitive and refractory relapses in extensive-stage small cell lung cancer in the era of immunotherapy.
    J Thorac Oncol. 2023 Sep 23:S1556-0864(23)02256.
    PubMed     Abstract available


  327. WANG X, Bai H, Zhang J, Wang Z, et al
    Genetic intra-tumour heterogeneity remodels the immune microenvironment and induces immune evasion in brain metastasis of lung cancer.
    J Thorac Oncol. 2023 Sep 15:S1556-0864(23)01079.
    PubMed     Abstract available


  328. FIGUEROA PU, Marques E, Cilento VJ, Giroux DJ, et al
    Completeness of Resection and Long-term Survival of Patients Undergoing Resection for Pathological T3 Non-small-cell Lung Cancer: An International Association for the Study of Lung Cancer Analysis.
    J Thorac Oncol. 2023 Sep 15:S1556-0864(23)01078.
    PubMed     Abstract available


  329. ZHANG S, Liu L, Shi S, He H, et al
    Bidirectional association between cardiovascular disease and lung cancer in a prospective cohort study.
    J Thorac Oncol. 2023 Sep 11:S1556-0864(23)00806.
    PubMed     Abstract available


    August 2023
  330. DACIC S, Travis W, Redman M, Saqi A, et al
    International Association for the Study of Lung Cancer Study of Reproducibility in Assessment of Pathologic Response in Resected Lung Cancers After Neoadjuvant Therapy.
    J Thorac Oncol. 2023 Aug 3:S1556-0864(23)00685.
    PubMed     Abstract available


  331. LIN SH
    Statin Use and Chemoradiation in Esophageal Squamous Cell Carcinomas: Ready for Prime Time?
    J Thorac Oncol. 2023;18:970-971.
    PubMed    


    July 2023
  332. RIMNER A, Ruffini E, Cilento V, Goren E, et al
    The International Association for the Study of Lung Cancer Thymic Epithelial Tumors Staging Project: An Overview of the Central Database Informing Revision of the Forthcoming (Ninth) Edition of the TNM Classification of Malignant Tumors.
    J Thorac Oncol. 2023 Jul 24:S1556-0864(23)00672.
    PubMed     Abstract available


    June 2023
  333. PIETROLUONGO E, De Placido P, Tortora M, Martinelli C, et al
    Impaired seroconversion after SARS-CoV-2 mRNA vaccine in patients with thymic epithelial tumors.
    J Thorac Oncol. 2023 Jun 28:S1556-0864(23)00634.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.